NASDAQ
10.04.26 | 22:00
6,920 US-Dollar
-6,55 % -0,485
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 06.03. | Why Shattuck Labs Stock Soared More Than 53% Higher This Week | 2 | The Motley Fool | ||
| 06.03. | Shattuck Labs stock maintained at Buy by TD Cowen on drug data | 1 | Investing.com | ||
| 05.03. | Insights into Shattuck Labs Q4 Earnings | 1 | Benzinga.com | ||
| 05.03. | Shattuck Labs, Inc Q4 Loss Drops | 2 | RTTNews | ||
| 05.03. | Shattuck Labs, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Shattuck Labs GAAP EPS of -$0.12 beats by $0.01 | 1 | Seeking Alpha | ||
| 05.03. | Shattuck Labs, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 05.03. | Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights | 442 | GlobeNewswire (Europe) | Phase 1 clinical trial of SL-325 ongoing, with data expected in the second quarter of 2026 -Phase 2 clinical trial of SL-325 in patients with Crohn's disease expected to initiate in the third quarter... ► Artikel lesen | |
| 05.02. | Shattuck Labs, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 28.01. | Piper Sandler stuft Shattuck Labs mit "Overweight" ein und sieht massives Aufwärtspotenzial | 4 | Investing.com Deutsch | ||
| 28.01. | Piper Sandler initiates Shattuck Labs stock with Overweight rating | 1 | Investing.com | ||
| 22.01. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.01. | Why Shattuck Labs Stock Soared in December | 1 | The Motley Fool | ||
| 15.12.25 | Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 01.12.25 | Shattuck Labs stock rating upgraded to Buy by H.C. Wainwright | 2 | Investing.com | ||
| 07.11.25 | Shattuck Labs GAAP EPS of -$0.14 | 1 | Seeking Alpha | ||
| 06.11.25 | Shattuck Labs, Inc.: Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 261 | GlobeNewswire (Europe) | -First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers - - Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 - - Appointments... ► Artikel lesen | |
| 06.11.25 | Shattuck Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.08.25 | Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease | 429 | GlobeNewswire (Europe) | - SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases - - The Company... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NUREXONE BIOLOGIC | 0,420 | +2,94 % | Realistische Perspektive: Erstmals funktionale Regeneration defekter Nerven?! | ||
| ONCO-INNOVATIONS | 0,370 | +1,23 % | Onco-Innovations unterzeichnet Kooperationsvereinbarung mit Partnern im Bereich F&E-Förderprogramme ("RDI Partners") und gründet Onco-Innovations AU Pty. Ltd., um die australische Phase-I-Strategie voranzutreiben | Das Unternehmen gibt auch eine Marketingvereinbarung bekannt
Vancouver, Kanada - 7. April 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN:... ► Artikel lesen | |
| FRACTYL HEALTH | 0,460 | -1,77 % | Fractyl Health, Inc.: Fractyl Health Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Completed randomization in REMAIN-1 Pivotal Cohort; topline 6-Month data expected in early Q4 2026 Received favorable FDA feedback on De Novo classification request; De Novo submission expected in... ► Artikel lesen | |
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,680 | -3,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) | - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment... ► Artikel lesen | |
| IMMUNOVANT | 24,500 | -4,48 % | IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints | ||
| ENLIVEN THERAPEUTICS | 45,320 | -0,66 % | H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details | ||
| ZENTALIS PHARMACEUTICALS | 6,630 | +50,17 % | Jefferies raises Zentalis stock price target on ovarian cancer trial data | ||
| VERA THERAPEUTICS | 45,000 | +9,92 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ALUMIS | 23,050 | +0,48 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,480 | -3,16 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipated... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 12,630 | 0,00 % | Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results | FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| ARCELLX | 114,83 | +0,03 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 16,360 | -5,54 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| EVOTEC | 4,530 | +0,09 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen |
SHATTUCK LABS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -6,55 % bei einem Aktienkurs von 6,920 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.